临床外科杂志 ›› 2026, Vol. 34 ›› Issue (2): 218-222.doi: 10.3969/j.issn.1005-6483.20250236

• 论著 • 上一篇    下一篇

非肌层浸润性膀胱癌病人血清内皮细胞特异性分子-1、胆碱酯酶、鸢尾素水平与膀胱灌注治疗后复发的关系

  

  1. 223800 江苏宿迁,江苏省人民医院宿迁医院(宿迁市第一人民医院)泌尿外科
  • 收稿日期:2025-03-14 接受日期:2025-03-14 出版日期:2026-02-25 发布日期:2026-02-25
  • 通讯作者: 刘豪,Email:313034280@qq.com
  • 基金资助:
    宿迁市科技计划项目(KY202205)

The relationship between the levels of serum endothelial cell specific molecule-1,cholinesterase and irisin in patients with non-muscle-invasive bladder cancer and recurrence after bladder perfusion therapy

  1. Department of Urology,Jiangsu Provincial People 's Hospital Suqian Hospital,Suqian First People 's Hospital,Jiangsu,Suqian 223800,China
  • Received:2025-03-14 Accepted:2025-03-14 Online:2026-02-25 Published:2026-02-25

摘要: 目的 探讨内皮细胞特异性分子-1(ESM-1)、胆碱酯酶(ChE)、鸢尾素与非肌层浸润性膀胱癌病人膀胱灌注治疗后复发的关系。方法 2019年12月~2022年12月收治的非肌层浸润性膀胱癌病人86例,所有病人均接受膀胱灌注治疗,治疗前检测血清ESM-1、ChE、鸢尾素水平,治疗后随访2年,统计复发情况。应用多因素Cox风险比例回归分析影响非肌层浸润性膀胱癌病人膀胱灌注治疗后复发的因素,受试者工作特征(ROC)曲线分析ESM-1、ChE、鸢尾素预测复发的价值。结果 低分化、TNM分期T1期非肌层浸润性膀胱癌病人血清ESM-1水平高于中高分化、TNM分期Ta期,血清ChE、鸢尾素水平低于中高分化、TNM分期Ta期,差异有统计学意义(P<0.05)。失访3例,余83例病人中复发11例,未复发72例。复发组和未复发组血清ESM-1水平分别为(4.89±0.42)ng/ml 和(4.17±0.53)ng/ml,P<0.05),ChE水平分别为(4618.35±531.29)U/L和 5663.27±502.71)U/L,鸢尾素水平分别为(21.06±3.46)ng/ml 和(25.00±3.06)ng/ml,两组比较差异有统计学意义(P<0.05)。TNM分期T1期、高ESM-1是非肌层浸润性膀胱癌病人膀胱灌注治疗后复发的危险因素(P<0.05),高ChE、高鸢尾素是其保护因素(P<0.05)。ESM-1、ChE、鸢尾素预测非肌层浸润性膀胱癌病人膀胱灌注治疗后复发的曲线下面积分别为0.776、0.726、0.664,联合预测曲线下面积为0.871,高于单独预测,差异有统计学意义(P<0.05)。结论 非肌层浸润性膀胱癌病人血清ESM-1水平增高,ChE、鸢尾素水平降低与膀胱灌注治疗后复发有关,三者联合在膀胱灌注治疗后复发预测中具有较高价值。

关键词: 非肌层浸润性膀胱癌, 膀胱灌注治疗, 复发, 内皮细胞特异性分子-1, 胆碱酯酶, 鸢尾素

Abstract: Objective To investigate the relationship between endothelial cell specific molecule-1 (ESM-1),cholinesterase (ChE),irisin and the recurrence of Non-muscle-invasive bladder cancer after bladder perfusion therapy.Methods A total of 86 patients with Non-muscle-invasive bladder cancer admitted to our hospital from December 2019 to December 2022were selected.All patients received bladder perfusion therapy.Serum levels of ESM-1,ChE and irisin were detected before treatment.After the treatment,they were followed up for 2 years and the recurrence was statistically analyzed.Multivariate COX proportional regression analysis was used to analyze the factors affecting recurrence in patients with Non-muscle-invasive bladder cancer after bladder perfusion therapy,and the value of ESM-1,ChE and irisin in predicting recurrence was analyzed by receiver operating characteristic (ROC) curve.ResultsThe serum ESM-1 level of Non-muscle-invasive bladder cancer patients at T1 stage of low differentiation and TNM stage was higher than that at Ta stage of middle and high differentiation and TNM stage,and the serum ChE and irisin levels were lower than that at Ta stage of middle and high differentiation and TNM stage (P<0.05).Three cases were lost to follow-up.Among the remaining 83 patients,11 relapsed and 72 did not relapse.Serum ESM-1 level in relapsed group was higher than that in non-relapsed group [(4.89±0.42)ng/ml vs. (4.17±0.53)ng/ml,P<0.05],ChE and irisin levels were lower than those in non-relapsed group [(4 618.35±531.29)U/L vs (5 663.27±502.71)U/L,(21.06±3.46)ng/ml vs (25.00±3.06 )ng/ml,P<0.05].TNM stage T1 and high ESM-1 were risk factors for recurrence of Non-muscleinvasive bladder cancer after bladder perfusion therapy (P<0.05),while high ChE and high irisin were protective factors (P<0.05).The area under the curve of ESM-1,ChE and irisin in predicting the recurrence of patients with Non-muscle-invasive bladder cancer after bladder perfusion therapy was 0.776,0.726 and 0.664,respectively,and the area under the curve of combined prediction was 0.871,which was higher than that of single prediction (P<0.05).Conclusion The increase of serum ESM-1 level and the decrease of ChE and irisin levels in patients with Non-muscle-invasive bladder cancer are related to the recurrence after bladder perfusion treatment,and the combination of the three is of high value in predicting the recurrence after bladder perfusion treatment.

Key words: Non-muscle-invasive bladder cancer, bladder perfusion therapy, recurrence, endocan or endothelial cell specific molecule-1, colinesterase;irisin

[1] 仵志远, 李华刚, 马卉. 动脉硬化闭塞症病人介入治疗后复发的预测模型构建[J]. 临床外科杂志, 2026, 34(1): 95-98.
[2] 汪俊 吕瑕智 陶玉 胡传朋. 血清微小核糖核酸-335-5p、内皮细胞特异性分子-1对食管癌病人的早期诊断及预后评估价值[J]. 临床外科杂志, 2025, 33(8): 836-840.
[3] 贠宇辉 姬翔 韩国梁 郭伟. 食管癌胸腔镜根治术中不同喉返神经旁淋巴结清扫对近期疗效、血清髓系细胞触发受体-1、肿瘤坏死因子受体相关蛋白-1水平及生存质量的影响[J]. 临床外科杂志, 2025, 33(5): 482-485.
[4] 陶家政, 冯世友, 陈刚. 肝胆管结石手术后复发风险模型建立与验证[J]. 临床外科杂志, 2025, 33(4): 416-419.
[5] 杨林 韩玉刚 梁想. 膀胱癌组织中微小RNA-433-3p、β微管蛋白V的表达与病理特征的关系及对术后复发的预测价值[J]. 临床外科杂志, 2025, 33(2): 175-178.
[6] 王秋红 王贤 许华胜 翟振. 血清透明质酸合成酶2、癌胚抗原、细胞角蛋白19水平对不同病理分型甲状腺癌中的诊断价值以及对术后复发的预测价值[J]. 临床外科杂志, 2025, 33(12): 1283-1286.
[7] 占学志 余金 朱媛 廖晓锋 李晓刚. 术前经肝动脉化疗栓塞术对Ⅰb~Ⅱa期肝癌早期复发的影响[J]. 临床外科杂志, 2025, 33(10): 1073-1076.
[8] 衣舜 柳爽爽 王耀鹏 王传孝 矫文捷. 血清长链非编码RNA Kinectin 1反义RNA 1和视网膜母细胞瘤结合蛋白4表达与食管癌病人术后复发转移的关系[J]. 临床外科杂志, 2025, 33(10): 1077-1081.
[9] 任雪康, 付雨, 朱少功, 张德志, 夏云展. 原发性腹股沟多形性未分化肉瘤复发一例[J]. 临床外科杂志, 2025, 33(1): 111-112.
[10] 任峰 周静瑜 周建平. 复发性腹股沟疝手术治疗相关问题探讨[J]. 临床外科杂志, 2024, 32(9): 908-909.
[11] 邵旻婧 黄晓 符德元. 乳腺皮肤隆突性皮肤纤维肉瘤一例[J]. 临床外科杂志, 2024, 32(9): 1001-1002.
[12] 李瑾 朱付英 徐娅 兰运彤. miR-27b-3p联合miR-215对早期胃癌内镜黏膜下剥离术后复发的预测效能[J]. 临床外科杂志, 2024, 32(8): 830-834.
[13] 蒋炳涧. 整形保乳手术在早期乳腺癌治疗中的效果和复发率分析[J]. 临床外科杂志, 2024, 32(3): 240-243.
[14] 向悦 陈德杰. 甲状腺乳头状癌术后颈侧区复发影响因素分析[J]. 临床外科杂志, 2024, 32(3): 248-251.
[15] 周涛 徐红梅 刘文佳. 胃癌术后病人胆碱酯酶水平与肌肉减少症及术后感染风险的相关性[J]. 临床外科杂志, 2024, 32(12): 1272-1275.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 宫念樵. 器官捐献供肾质量评估[J]. 临床外科杂志, 2016, 24(10): 729 .
[2] 黄洪锋. 关注公民逝世后器官捐献肾移植受体围手术期感染的预防与处理[J]. 临床外科杂志, 2016, 24(10): 732 .
[3] 邱江. 心脏死亡捐献供肾移植免疫抑制方案的选择[J]. 临床外科杂志, 2016, 24(10): 735 .
[4] 林俊. 原发性中枢神经系统恶性肿瘤供者在器官移植中的应用[J]. 临床外科杂志, 2016, 24(10): 737 .
[5] 胡善彪;余少杰;彭龙开. 婴幼儿供肾移植[J]. 临床外科杂志, 2016, 24(10): 741 .
[6] 昌盛. 中国心脏死亡捐献供肾器官的维护[J]. 临床外科杂志, 2016, 24(10): 744 .
[7] 杨华;李新长;龙成美;等. 公民逝世后器官捐献供肾移植临床分析[J]. 临床外科杂志, 2016, 24(10): 747 .
[8] 石宇;刘学刚 . 冠状动脉旁路移植术后短期内应用强化他汀对患者出血风险的研究[J]. 临床外科杂志, 2016, 24(10): 750 .
[9] 陈忠;王耀东;田毅峰;等. 肝胆管结石病规范化治疗的临床分析[J]. 临床外科杂志, 2016, 24(10): 753 .
[10] 齐卫鹏;王剑明;刘颜;等. 术前应用靛氰绿检测联合三维重建成像评估肝门部胆管癌肝脏储备功能[J]. 临床外科杂志, 2016, 24(10): 756 .